BioDelivery Sciences International, Inc. (BDSI) Receives $4.80 Consensus Price Target from Analysts

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $4.80.

Several analysts have issued reports on BDSI shares. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Cantor Fitzgerald set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, October 26th. BidaskClub cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a report on Friday, August 10th. Finally, Janney Montgomery Scott upped their target price on BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a report on Friday, November 2nd.

In other news, Director Francis E. Odonnell, Jr. sold 151,039 shares of the stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the transaction, the director now directly owns 520,482 shares in the company, valued at approximately $1,478,168.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $3.84, for a total value of $30,720.00. Following the transaction, the director now owns 522,187 shares of the company’s stock, valued at $2,005,198.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 167,039 shares of company stock valued at $481,671. Company insiders own 13.26% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new position in shares of BioDelivery Sciences International during the 2nd quarter worth $138,000. PNC Financial Services Group Inc. purchased a new position in shares of BioDelivery Sciences International during the 2nd quarter worth $148,000. Worth Venture Partners LLC purchased a new position in shares of BioDelivery Sciences International during the 3rd quarter worth $167,000. Dimensional Fund Advisors LP purchased a new position in shares of BioDelivery Sciences International during the 3rd quarter worth $255,000. Finally, Wells Fargo & Company MN grew its holdings in shares of BioDelivery Sciences International by 121.7% during the 3rd quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock worth $331,000 after purchasing an additional 64,803 shares during the period. Institutional investors and hedge funds own 44.01% of the company’s stock.

NASDAQ:BDSI traded down $0.01 during trading hours on Monday, hitting $3.62. The company had a trading volume of 335,672 shares, compared to its average volume of 520,724. The company has a quick ratio of 2.77, a current ratio of 3.00 and a debt-to-equity ratio of 1.42. The stock has a market cap of $256.67 million, a P/E ratio of -9.28 and a beta of 0.09. BioDelivery Sciences International has a 1 year low of $1.70 and a 1 year high of $4.14.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.04. The company had revenue of $14.16 million during the quarter, compared to analysts’ expectations of $14.21 million. BioDelivery Sciences International had a negative return on equity of 141.35% and a negative net margin of 85.93%. On average, equities analysts anticipate that BioDelivery Sciences International will post -0.61 earnings per share for the current year.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: How Short Selling Works

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply